Table 3 Distribution of patients having the MTRR 66 AA/AG genotypes according to tumor stage, tumor differentiation grade, and therapy conditions, after dichotomization by p16 hypermethylation status
| Â | No p16 hypermethylation, n (%) | p16 Hypermethylation, n (%) | P a |
|---|---|---|---|
Tumor stage | Â | Â | Â |
I + II | 35 (59) | 19 (63) | Â |
III | 24 (41) | 11 (37) | 0.82 |
Tumor differentiation grade | Â | Â | Â |
Low/medium | 40 (68) | 20 (67) | Â |
High | 19 (32) | 10 (33) | 1.0 |
Adjuvant chemotherapy | Â | Â | Â |
No | 47 (80) | 26 (87) | Â |
Yes | 12 (20) | 4 (13) | 0.56 |
Presurgical radiotherapy | Â | Â | Â |
No | 49 (83) | 25 (83) | Â |
Yes | 10 (17) | 5 (17) | 1.0 |